Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aptose Biosciences, Inc. (APTO)

Add APTO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 12/17/2017 12:47:14 PM - Followers: 7 - Board type: Free - Posts Today: 0

Lorus Therapeutics Implements Name Change to Aptose Biosciences;_ylt=AwrTWf0ydBdUH3AAFBWTmYlQ


Business Information:

Aptose Biosciences. Inc.
Ticker: APTO
PPS: 1.64    a/o     7/13/2017
Up 0.12 points or 7.89%
Market Value: $23,895,510 a/o July 12, 2017
Outstanding Shares: 15,721,388 a/o Dec 31, 2016
APTOSE Website:

Fundamental analysis:

According to Aptoses’ website, Aptose Biosciences is a biotechnical company that looks to find treatments for cancers. These cancers include acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and other hematologic malignancies.
From their research, they have discovered that “CG026806 (CG’806) is a highly potent first-in-class pan-FLT3/BTK inhibitor.” This knowledge is aiding their fight against chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), large B cell lymphoma (DLBCL), and more. Aptose also has another program called APTO-253 which is also aiding to treat cancer.
Aptose Management:
William G. Rice, Ph.D.  Chief Executive Officer (CEO)
Daniel D. Von Hoff, M.D., F.A.C.P. Senior Vice President, Medical Affairs
Stephen B. Howell, M.D. Acting Chief Medical Officer
Avanish Vellanki Chief Business Officer (CBO)
Gregory Chow Chief Financial Officer (CFO)                  
Institutional Ownership 11.11 %
Total Institutional Shares: 2,417,492
NASDAQ APTO Institutional Ownership Link
No Insider Traders
Possible Float: ~13,303,896
Looking at Aptoses’ income statement, they have a running loss with $0 in revenue. For the first quarter of 2017, the company had a net loss of ~$4,355,000. Also, over the course of the last year, the company has had a net loss of ~$17,910,000. Unless the company can create and sell one of their cures, Aptose will continue to run at a loss. If the company was to sell one of their cures, it comes down to how effective and efficient the drug is. These medicines would help it penetrate a full cancer treatments market. There is the possibility that the drugs and treatments could sell very well, but there is serious doubt that such an event will happen.
Aptoses’ balance statement shows that it has ~11,958,000 in on hand cash Q1 2017. From what we were able to find, the company is gaining on-hand cash from selling company shares to investors. In total, Aptose has a total of ~$12,676,000 in assets for Q1 2017. For accounts payable, Aptose has ~$2,340,000 in current liabilities. For shareholders equity, investors of Aptose have ~$235,869,000 in shares. The accumulated deficit for investors is ~$247,877,000.
On 6/8/2017, the company got rated as neutral by Rodman & Renshaw. Also, analysts rated the stock as a buy with a price target of $9. In forward-looking thoughts, $9 is a very optimistic number to put on a stock that currently doesn’t have any income, and is relying solely on investors. Our forward-looking though suggests that the stock will continue its period of consolidation until either they run out of funds or release a new product. Depending on the event, the price per share will reflect the positive or negative aspects of that event.
On 6/6/2017, the company held an annual meeting of shareholders. During this press release, the voting results for the company’s board of directors were released. Also, the company told shareholders that they displayed CG’806 in a presentation last month in Boston. From the press release, they stated that the product/treatment was performing well during their tests." rel="nofollow">Read More Here

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APTO News: Report of Foreign Issuer (6-k) 12/11/2017 04:05:41 PM
APTO News: Report of Foreign Issuer (6-k) 12/11/2017 04:05:41 PM
APTO News: Securities Registration (foreign Private Issuer) (f-1) 11/28/2017 04:18:16 PM
APTO News: Report of Foreign Issuer (6-k) 11/14/2017 05:27:03 PM
APTO News: Report of Foreign Issuer (6-k) 11/14/2017 04:56:55 PM
#73   whats not to like---now i know to stay ernie44 12/17/17 12:47:14 PM
#71   3 year high decended to 8, then ernie44 12/07/17 04:18:15 PM
#70   When are you going to call a stockmoneybaby 11/13/17 06:50:13 PM
#69   * * $APTO Video Chart 11-13-17 * * ClayTrader 11/13/17 05:22:27 PM
#68   Aptose Biosciences. Inc. Forward-Looking Analysis Decatsmeow 08/10/17 04:27:59 AM
#67   Buy Aptose Biosciences. Inc. (APTO) As Analysts Give Decatsmeow 08/10/17 04:20:10 AM
#66   APTO buy 1.45 stocktrademan 07/21/17 11:50:47 AM
#65   I believe this stock will rise up to Decatsmeow 07/18/17 02:22:17 AM
#64   Honestly, for a publically traded company that doesn't Decatsmeow 07/18/17 02:21:29 AM
#63   There's a upward trend emerging her. Get your Decatsmeow 07/18/17 02:20:49 AM
#62   I wrote a great article/blog about this stock. Decatsmeow 07/18/17 02:20:19 AM
#61   * * $APTO Video Chart 07-03-17 * * ClayTrader 07/03/17 02:27:37 PM
#60   Starting to get interesting. Dr. Rice is a genius. Regis999 06/28/17 05:36:44 PM
#59   * * $APTO Video Chart 06-13-17 * * ClayTrader 06/13/17 04:52:58 PM
#58   LYTTON LAURENCE W has filed a new 13G, wiltonio 06/09/17 06:07:25 AM
#57   Somebody just bought premarket - 8,450 shares at $1.30 Depcom 05/05/17 08:28:59 AM
#56   Not that I've seen. Depcom 05/05/17 08:27:39 AM
#55   I'm going to hold for higher prices, but tjguy 05/05/17 08:24:05 AM
#54   The way I see it, we should be Depcom 05/05/17 08:21:57 AM
#53   Not only that! If you hold for a tjguy 05/05/17 08:08:16 AM
#52   Grabbed some shares Friday at.86, it's up about Depcom 05/04/17 06:00:55 PM
#51   Oh, OUCH! Sorry to hear that! tjguy 05/04/17 04:30:34 PM
#50   those dang phase trials drain my bank acct.. ernie44 05/04/17 01:07:45 PM
#49   Some nice action the last couple of days! tjguy 05/04/17 08:27:10 AM
#48   one heckuva sow cow drainer ernie44 01/23/17 02:00:07 PM
#47   Ha! Yeah way down. -_- Sell High -_- 01/23/17 11:16:32 AM
#46   this flea infested dog now has hip displacia ernie44 01/23/17 10:45:44 AM
#45   where u been sweety-pie did they make ernie44 12/09/16 04:13:16 PM
#44   lets hope for the rebound -_- Sell High -_- 11/03/16 08:04:34 AM
#43   yeah, I'm feeling the same way -_- Sell High -_- 11/03/16 08:03:42 AM
#42   Bought a few today. I did very well vixpix 11/01/16 10:39:24 PM
#41   After some DD..I purchased on Friday. The technicals Lama 10/30/16 01:57:10 PM
#40   I can see this going back to around -_- Sell High -_- 10/28/16 02:25:10 PM
#39   Lots of room to rebound, imp -_- Sell High -_- 10/28/16 02:24:31 PM
#38   ship should come in today-- not like last pattiofurniture 04/17/13 09:03:38 AM
#37   you still in this? I got in serafin1982 05/01/12 10:16:33 PM
#36   The 1 for 30 reverse split will most Norm2 05/13/10 01:44:00 PM
#35   Will post something about Viruizin and IL-17E Norm2 02/26/10 01:06:17 PM
#34   The latest PR gives me new hope for Virulizin. Norm2 02/25/10 11:51:10 AM
#33   Finances Norm2 10/07/09 04:26:36 PM
#32   A recent PR gave a status of Lorus: Norm2 07/30/09 11:29:18 AM
#31   News about LOR-2040 Norm2 06/29/09 12:51:11 PM
#30   "TORONTO, ONTARIO--(Marketwire - June 22, 2009) - Lorus Norm2 06/23/09 11:37:53 AM
#29   Re: Lorus Presentation Norm2 11/12/08 12:31:23 PM
#28   Lorus Presentation Norm2 11/11/08 10:18:37 AM
#27   On LOR.TO news Norm2 11/10/08 10:35:29 AM
#26   Lorus is now trading as LRUSF.PK. Norm2 11/06/08 02:47:57 PM
#25   Todays news is hopeful. It sounds like ZOR Norm2 10/15/08 09:53:20 AM
#24   LRP is leaving. Norm2 10/10/08 08:18:05 PM
#23   Thanks for the link GG88 10/01/08 05:36:52 PM